Kornimate/medical-research-clean huggingface dataset:
s9923 r115777 in treating patients with advanced colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of r115777 in treating patients who have recurrent or advanced colorectal cancer.

objectives: i. determine the response rate to r115777 in patients with disseminated colorectal cancer who have been previously treated for advanced disease. ii. assess the time to treatment failure and survival of these patients with this treatment regimen. iii. determine the frequency and severity of toxicities of this regimen in these patients. outline: this is a multicenter study. patients receive oral r115777 twice daily on days 1-21. treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. patients are followed every 6 months for 2 years and then annually thereafter. projected accrual: a total of 50 patients will be accrued for this study over 5-7 months.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed advanced colorectal adenocarcinoma well differentiated or moderately well differentiated or poorly differentiated distant metastases not surgically curable measurable disease no prior treatment for disseminated disease no known brain metastases patient characteristics: age: 18 and over performance status: zubrod 0-1 life expectancy: not specified hematopoietic: absolute granulocyte count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) sgot or sgpt no greater than 2.5 times uln renal: creatinine no greater than 2.0 mg/dl other: not pregnant or nursing fertile patients must use effective contraception must be able to swallow or receive enteral medications through gastrostomy feeding tube no intractable nausea or vomiting no other prior malignancy for the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any adequately treated stage i or ii cancer in complete remission prior concurrent therapy: biologic therapy: at least 4 weeks since prior adjuvant immunotherapy and recovered no concurrent immunotherapy chemotherapy: at least 4 weeks since prior adjuvant chemotherapy and recovered no other concurrent chemotherapy endocrine therapy: no concurrent hormonal therapy radiotherapy: at least 4 weeks since prior radiotherapy and recovered no more than 25% of total area of bone marrow irradiated no concurrent radiotherapy surgery: at least 2 weeks since prior surgery and recovered other: no concurrent proton pump inhibitors no other concurrent anticancer therapy

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum
a study of ly2157299 in participants with unresectable hepatocellular cancer (hcc)

Conditions: Hepatocellular Carcinoma

Summary: the main purpose of this study is to evaluate safety and tolerability of ly2157299 when combined with sorafenib in japanese hepatocellular carcinoma (hcc) participants.


Eligibility criteria:
inclusion criteria: * have histological evidence of a diagnosis of hcc (except hcc with fibrolamellar or mixed histology) not amenable to curative surgery. * have child-pugh class a. * have the presence of measurable or evaluable lesion as defined by the response evaluation criteria in solid tumors (recist) v1.1. a measurable or evaluable lesion showing demonstrable progression after locoregional therapy could be also included. * have not received sorafenib prior to enrollment. * have resolution to grade less than or equal 1 by the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.03 of all clinically significant toxic effects of prior locoregional therapy, surgery, chemoembolization, systemic chemotherapy. * have a performance status of less than or equal 1 on the eastern cooperative oncology group (ecog) scale. exclusion criteria: * are currently enrolled, or discontinued within 28 days prior to enrollment from, a clinical trial involving an investigational product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * have undergone major surgery within 28 days prior to enrollment. * have undergone hepatic locoregional therapy (including radiation, surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, cryoablation, percutaneous ethanol injection, or percutaneous microwave coagulation therapy) within 28 days prior to enrollment. * have moderate or severe cardiac disease. * myocardial infarction within 6 months prior to enrollment, unstable angina pectoris, new york heart association (nyha) class iii/iv congestive heart failure, or uncontrolled hypertension. * documented major electrocardiogram (ecg) abnormalities at the investigator's discretion within 28 days prior to enrollment. * major abnormalities documented by echocardiography with doppler at investigator's direction within 28 days prior to enrollment. * have persistently elevated brain natriuretic peptide (bnp) or elevated troponin i within 14 days prior to enrollment. * predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress. * have a history of cardiac or aortic surgery. * have undergone liver transplant. * are pregnant or breastfeeding.
anti-t-lymphocyte globulin (atg) in renal transplantation of kidneys with a non-heart-beating (nhb) donor

Conditions: Renal Transplant Patients; Recipients of a Kidney From a Non-Heart-Beating Donor

Summary: one of the greatest problems in renal transplantation is the shortage of donor kidneys. kidneys of non-heart-beating donors (nhb) are a possible solution, but transplantation is accompanied with a high percentage of acute renal failure, caused by ischemia-reperfusion injury. the increased ischemia-reperfusion injury results in an increased immune activation, which can lead to more injury of the kidney and additional acute rejections. the hypothesis of this trial is that ischemia-reperfusion injury can be diminished by atg. atg could have additional favourable effects. to investigate this half of the patients is treated with additional atg to the standard immunosuppressive treatment. calcineurin inhibitors are not diminished during the first days after transplantation to investigate whether atg has special effects on ischemia-reperfusion injury.


Eligibility criteria:
inclusion criteria: * non-heart-beating-donors (maastricht iii/iv) * female patients of childbearing age agree to maintain effective birth control practice during the study. exclusion criteria: * pregnant or lactating women at the time of randomization. * patients and donors are abo incompatible. * women having had \>3 pregnancies (including abortions if no consistent data on pra or anti-donor antibodies are available). * patients with hypersensibility to rabbit proteins, previous treatment with rabbit igg, or known intolerance to any component of basal immunosuppression. * patients with leukocytes \<3,000/mm3 and/or platelets \<50,000/mm3 before initiation of transplant. * patients, who are hiv positive. * patients subjected to previous transplants or candidates for multiple transplants (e.g. skp). * patients, who are unlikely to comply with the visit schedule in the protocol and patients who cannot communicate reliably with the investigator. * patients with pulmonary oedema or with other signs of overhydration.

Keywords: kidney transplantation non-heart-beating donor delayed graft function antithymocyte globulin ischemia-reperfusion damage
pain reduction and ovarian perfusion following uterine fibroid embolization

Conditions: Uterine Bleeding; Uterine Fibroid

Summary: the goal of this study is to assess of pressure-enabled drug delivery on fibroid treatment in patients undergoing ufe.

uterine fibroids are the most common tumor type in women of reproductive age and may be associated with abnormal menstrual bleeding, pain, sub-fertility, and diminished quality of life. for women interested in uterine preservation who want to derive adequate relief from medical management, uterine fibroid embolization (ufe) is a treatment option. the goal of this study is to assess of pressure-enabled drug delivery on fibroid treatment in patients undergoing ufe.

Eligibility criteria:
inclusion criteria: 1. female, aged \>18 years. 2. prior clinical decision for treatment by ufe. 3. one or more enhancing intramural, submucosal or subserosal fibroids on mri. 4. having either bulk symptoms or menorrhagia. exclusion criteria: 1. absolute contraindication to contrast-enhanced mri. 2. current pregnancy. 3. known history of adenomyosis. 4. diagnosis of pelvic inflammatory disease. 5. diagnosis of endometriosis. 6. post-menopausal (no menses \>12-months). 7. diagnosed gynecologic malignancy. 8. prior uterine fibroid embolization treatment. 9. \>50% volume of non-enhancing fibroids. 10. prior oophorectomy 11. gnrh agonist therapy within 6-months or gnrh antagonist therapy within 1-month prior to entering the study. 12. target uterine vasculature not suitable for treatment with the trinav infusion system. 13. allergy or intolerance to dilaudid. 14. lack of ovarian perfusion on baseline mri.
electronic mobile phone app stool diary

Conditions: Constipation; Incontinence Bowel

Summary: our objective here is to improve the patient's compliance and accurate capture of patient reported bowel and abdominal symptoms, by utilizing a phone application that interactively records each bowel movement or leakage event and other bowel symptoms. such an electronic stool diary may relieve the burden of using a paper daily stool diary. we will compare and validate the electronic stool diary with the paper stool diary.

fecal incontinence consists of multiple and often unpredictable bowel movements and leakage of stool. chronic constipation is associated with episodes of irregular and unpredictable bowel habits and difficulty with remembering symptoms. these features lead to a recall bias, and inaccurate recollection and/or documentation of symptoms that are critical for diagnosis and management. a daily stool diary has been used in clinical trials and in clinical practice to accurately record bowel symptoms. however, patients find these diary entries cumbersome or embarrassing to use, especially with bowel movements that occur outside of home resulting in loss of data or inaccurate collection of information. also, many patients forget events especially when this bowel habit is irregular. therefore, it is crucial to explore new ways of accurately, reliability, and more discretely collect bowel habit information, by using current technology that a majority of people have access to.

Eligibility criteria:
inclusion criteria: * anyone older than 18 years with symptoms of fecal incontinence (fi), constipation, or healthy (i.e. no bowel issues). * women of childbearing age will be asked if they are pregnant, and a confirmed negative response is given will be sufficient. no pregnancy test will be performed. exclusion criteria: * none
photodynamic therapy (pdt) with methyl aminolevulinate (mal) cream in patients with skin type v or iv with acne vulgaris

Conditions: Acne Vulgaris

Summary: in this multicenter study, patients with dark skin and acne vulgaris will be included. the patients will receive treatment with mal pdt and placebo pdt.

the treatment period started within 2 weeks of the study screen. patients received two treatments (mal pdt and vehicle pdt) to each of the treatment areas, 2 weeks apart, and were followed-up 4 weeks after last treatment. the total duration of the study was 6-8 weeks. methyl aminolevulinate 80 mg/g cream (mal cream 8%)and vehicle was applied for 1.5 hours before illumination (aktilite® cl128), total light dose 37 j/cm2

Eligibility criteria:
inclusion criteria: 1. female and male patients, age 15 to 40 years with acne vulgaris. 2. patients with skin type v or vi (fitzpatrick). 3. patients with two areas of each 8x8 cm2 on the back that include at least 5 inflammatory lesions (papules, pustules, and nodules) each. the minimum distance between the two areas should be at least 4 cm. 4. patients with no more than 2 nodular lesions in any of the two areas of each 8x8 cm2 on the back. 5. patients who are surgically sterile, postmenopausal, abstinent, or willing to use an adequate means of contraception including birth control pills, or barrier methods and spermicide for at least 14 days prior to day 0. patients using birth control pills must have used the same product and dose for at least 3 months and must agree to stay with the same product and dose for an additional 3 months. 6. patients must be willing and capable of following study instructions to the extent and degree required by the protocol. 7. patients must sign the approved informed consent form prior to any study procedures. 8. patients must be willing to be photographed. patients must be willing to sign a photography consent form. exclusion criteria: 1. known allergy to mal, to a similar pdt compound, or to excipients of the cream. 2. participation in other clinical studies either concurrently or within the last 30 days. 3. patients who have a condition or who are in a situation, which, in the investigator's opinion, may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the study. 4. clinically significant sensitivity to visible light, or has porphyria or porphyrin sensitivity. 5. exposure to ultraviolet radiation (uvb phototherapy) within the last 30 days. 6. patients with a washout period for topical treatments for their acne in the two treatment areas of less than 14 days. any topical treatment on the face or other areas outside the two treatment areas will be allowed. 7. patients with a washout period for oral antibiotics for treatment of their acne of less than 1 month. 8. patients with a washout period for oral isotretinoin of less than 6 months.
relationship between ani, anxiety, and pain in conscious hernia patients undergoing csea

Conditions: Combined Spinal-epidural Anesthesia

Summary: analgesia nociception index can be used to detect noxious stimulation during general anesthesia.the aim of this study is to observe ani under combined spinal epidural anesthesia procedures in conscious hernia patients.

analgesia nociception index which is derived by heart rate variability, can be used to detect noxious stimulation during general anesthesia. however, the impact of anxiety on ani evaluation and the correlation between ani, pain, and anxiety in awake patients remains unclear. this study aimed to investigate the correlation between ani, pain, and anxiety in conscious hernia patients undergoing combined spinal epidural anesthesia procedures.

Eligibility criteria:
inclusion criteria: * age between 18- 80 years * asa physical status i or ii * scheduled for inguinal hernia, umbilical hernia or incisional repair under csea * written informed consent exclusion criteria: * use of cns-active medication or abuse of alcohol * history of cardiac arrhythmia * contraindications of combined spinal epidural anesthesia * previous exposure to csea or surgery
mi mortality risk and between-hospital risk variation in the united kingdom and sweden

Conditions: Acute Myocardial Infarction

Summary: the study aims to investigate the differences in survival trajectories and hospital variability in myocardial infarction (mi) mortality rates in the uk and sweden.

limited evidence is available in comparing hospital level care and reference mortality risks between countries, due to the scarce availability of nationwide coronary heart disease data. the demographics and medical expenditure percentage are comparable in the united kingdom and sweden; however, the in-hospital case-fatality rates within 30 days after admission for acute myocardial infarction was greater in the uk than sweden (6.3% versus 2.9%)(oecd, 2009). to investigate the discrepancy, the current study aims to compare the mortality risk differences and associated explanatory factors between the two countries. results of the study can contribute to myocardial infarction care implementation in the uk and sweden. the uk myocardial ischaemia national audit project (minap)and register of information and knowledge about swedish heart intensive care admissions (riks-hia) are few quality national registries currently available for acute coronary syndrome. using data from the minap and riks-hia, we propose to investigate (1)the survival trajectories for a reference patient with myocardial infarction and (2) hospital variability in myocardial infarction mortality rate in the uk and sweden, adjusted for important patient-level and hospital-level covariates.

Eligibility criteria:
inclusion criteria: * patients aged above 30 years old who had hospital admission for acute myocardial infarction. * admission period ranged from 1st january, 2004 to 31th december, 2008. exclusion criteria: * patients with missing data in the admission time and/or primary outcomes.

Keywords: myocardial infarction uk sweden national audit registry minap riks-hia
association between vitamin d and perioperative hemoglobin levels in patients undergoing off-pump coronary artery bypass graft surgery: role of hepcidin

Conditions: Coronary Artery Disease

Summary: preoperative anemia is present in more than 50% of patients undergoing cardiac surgery, which is associated with increased risk of transfusion, increased length of stay in the intensive care unit, and increased incidence of renal failure and mortality. to date, clinical research on perioperative anemia has been focused on finding and treating other underlying causes of anemia, lowering the threshold for transfusion, and performing careful transfusion. however, recently, it was known that hepcidin and erythroferrone are related to iron metabolism and absorption, vitamin d has an inverse correlation with the development of anemia, and is related to hepcidin concentration control. therefore, in this study, the relationship between vitamin d, hepcidin concentration and perioperative hemoglobin level in patients with off-pump coronary artery bypass graft surgery was investigated together.


Eligibility criteria:
inclusion criteria: 1. patients over 20 years of age undergoing off-pump coronary artery bypass graft exclusion criteria: 1. emergency operation 2. minimal invasive coronary artery bypass graft 3. cooperative operation with other surgery 4. patients who need a mechanical ventricular assist device 5. patients with chronic kidney disease (egfr \< 30) 6. patients who have a end stage renal disease and need a hemodialysis 7. patients with a low hemoglobin (hb \< 10) before surgery 8. patients who have a some disease(leukemia, myeloma, aplastic anemia, sickle cell anemia, etc) affecting hematopoiesis 9. patients with a liver cirrhosis 10. patients who receive vit. d, iron supplements, erythropoietin within 6 months 11. patients who cannot understand the informed consent (eg. foreigner, patients with cognitive dysfunction, etc) 12. patients who disagree this study
robotics as a useful tool to improve the hydration of the elderly

Conditions: Dehydration; Daily Fluid Intake; Urinary Infections

Summary: the aim of this clinical trial is to evaluate the effectiveness of a hydration educational program executed through a robot in comparison with the usual hydration program in terms of fluid intake and general health status of the residents. the main question to be answered is whether the use of robotics through a humanoid robot increases the hydration of institutionalized older people. participants: * the intervention group will receive a hydration plan executed by the robot and the control group will receive the center\&#39;s usual hydration plan. * healthcare personnel will receive reminders from the robot to record fluid intake through it. in the control group, health personnel will perform the fluid intake record in paper format and at the end of the shift, as usual.


Eligibility criteria:
inclusion criteria: * age equal to or greater than 65 years. no exclusion criteria have been established.

Keywords: dehydration aged nursing homes robotics fluid intake
price survey of extubation following infratentorial craniotomy

Conditions: Infratentorial Neoplasms

Summary: the price study primarily aims to identify predictors of early extubation following elective infratentorial craniotomy in adults. it also aims to (i) measure the rate of early extubation in different clinical settings; and (ii) study how the decision to extubate early is made and communicated in clinical practice. the first phase of the study (price1) is a brief online survey addressed to physicians in charge of neurosurgical patients (neuroanesthesiologists, neurosurgeons, neurocritical care specialists) in multiple countries.


Eligibility criteria:
inclusion criteria: * physician actively involved in delivering care to neurosurgical patients * physician formerly involved in delivering care to neurosurgical patients exclusion criteria: * has already completed the survey

Keywords: airway extubation prediction prevalence survey
comparison efficiency of oral etoricoxib versus intravenous fentanyl on post operative pain in curettage under tiva

Conditions: Abnormal Uterine Bleeding

Summary: comparison of the efficiency of oral etoricoxib versus intravenous fentanyl on post operative pain in curettage under tiva: a randomized controlled trial

fractional curettage is the most widely used for diagnostic and treatment abnormal uterine bleeding. the patient categorize post-operative pain as mild to moderate. therefore, the effective analgesic added on intraoperative and post-operative is the most important factor in patient's satisfaction, patient well co-operation, shortness time of operation, decrease unpleasant symptoms and rapid recovery. however, there are many anesthetic technique that can be used to relive pain in the operation such as local anesthesia, total intravenous anesthesia, regional anesthesia or oral analgesic drugs. intravenous fentanyl is an short acting opioid. it has a fast onset of action within 2 minutes and short duration of action 30-60 minutes. respiratory depression, hypotension and bradycardia are adverse effects that might delayed discharge especially in one day surgery e.g. fractional curettage. etoricoxib is an oral cox-2 specific inhibitor which can be used to relieve the pain. the onset of analgesia can be occurred within 24 minutes which peak plasma level within 60 minutes. there are many empirical evidences to support the results of post-operative pain after used oral etoricoxib or intravenous fentanyl. however, there are less evidences to support efficiency of oral etoricoxib versus intravenous fentanyl on post-operative pain in fractional curettage under tiva

Eligibility criteria:
inclusion criteria: * women who having abnormal uterine bleeding undergoing fractional curettage under tiva exclusion criteria: * women who have opioid or nsaids allergy * women who disagree to participate in this study * women who have history of gastrointestinal bleeding or ulcer * women who have abnormal kidney function * women who can't understand thai language * women who have american society of anesthesiologists \[asa\] above 2 * women who have been used nsaids in 48 hours or often used nsaids